Stock 1099 SINOPHARM GROUP CO. LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Sinopharm Group Co. Ltd. Stock

Equities

1099

CNE100000FN7

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 10:11:41 2024-07-02 pm EDT 		5-day change 1st Jan Change
20.9 HKD +0.48% Intraday chart for Sinopharm Group Co. Ltd. 0.00% +2.20%
Jun. 13 Sinopharm Group Co. Ltd. Declares Final Dividend for the Fiscal Year Ended December 31, 2023, Payable on 13 August 2024 CI
Jun. 10 Sinopharm Group Withdraws Resolution to Appoint PwC as Auditors MT

Financials

Sales 2024 * 647B 88.98B 695B Sales 2025 * 704B 96.84B 757B Capitalization 60.4B 8.31B 64.91B
Net income 2024 * 9.64B 1.33B 10.36B Net income 2025 * 10.6B 1.46B 11.39B EV / Sales 2024 * 0.11 x
Net Debt 2024 * 10.04B 1.38B 10.79B Net Debt 2025 * 5.72B 787M 6.15B EV / Sales 2025 * 0.09 x
P/E ratio 2024 *
6.26 x
P/E ratio 2025 *
5.7 x
Employees 115,959
Yield 2024 *
4.83%
Yield 2025 *
5.3%
Free-Float 42.99%
More Fundamentals * Assessed data

Chart Sinopharm Group Co. Ltd.

Dynamic Chart

Latest news about Sinopharm Group Co. Ltd.

Sinopharm Group Co. Ltd. Declares Final Dividend for the Fiscal Year Ended December 31, 2023, Payable on 13 August 2024 CI
Sinopharm Group Withdraws Resolution to Appoint PwC as Auditors MT
BPH Global to Source Bird's Nest Products from China's Sinopharm; Shares Plummet 40% MT
China Grants Registration Approval for Shanghai Shyndec Pharmaceutical Unit's Flu Injection MT
China Traditional Chinese Medicine, Sinopharm Update on Privatization Process Status MT
Wall Street Cues, Property Outlooks Lift Asian Stock Markets MT
China, Hong Kong stocks rise, led by property shares RE
Sinopharm Group Co. Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Sinopharm Group Shares Fall as Higher Costs Cut Into Quarterly Profit DJ
Sinopharm Group's Q1 Profit Falls as Operating Costs Rise MT
Central Bank, Tech Outlooks Lift Major Asian Stock Markets MT
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets MT
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator MT
Sinopharm's Attributable Profit Jumps in 2023 on Higher Revenue MT
More news

Analyst Recommendations on Sinopharm Group Co. Ltd.

Sinopharm Group Withdraws Resolution to Appoint PwC as Auditors MT
Nomura Adjusts Sinopharm Group’s Price Target to HK$32.39 Form HK$33.31, Keeps at Buy MT
Nomura Adjusts Sinopharm Group's Price Target to HK$33.31 From HK$36.28, Keeps at Buy MT
Nomura Adjusts Sinopharm's Price Target to HK$36.28 From HK$36.88, Keeps at Buy MT
UBS Adjusts Sinopharm Group's Price Target to HK$26 From HK$28, Keeps at Buy MT
More recommendations

Press releases Sinopharm Group Co. Ltd.

Sinopharm : 2023 Interim Results Presentation PU
Sinopharm : 2022 Annual Results Presentation PU
Sinopharm : 2022 Interim Report PU
Sinopharm : 2021 Interim Report PU
Sinopharm : FORM OF PROXY FOR DOMESTIC SHAREHOLDERS' CLASS MEETING PU
More press releases

News in other languages on Sinopharm Group Co. Ltd.

Borse Cina : chiudono miste, in rialzo Hong Kong con decisione su tassi
MÄRKTE ASIEN/Trotz Zinssenkung erneute Verluste in Hongkong und Schanghai
MORNING BRIEFING - USA/Asien
Borsa: Country Garden in uscita dall'Hang Seng di Hong Kong
MÄRKTE ASIEN/Erneute Abgaben in Hongkong und Schanghai
More news

Quotes and Performance

1 day+0.24%
1 week-3.26%
Current month+0.24%
1 month-1.89%
3 months+3.74%
6 months+1.71%
Current year+1.71%
More quotes

Highs and lows

1 week
20.35
Extreme 20.35
21.55
1 month
20.35
Extreme 20.35
22.90
Current year
17.44
Extreme 17.44
23.00
1 year
17.44
Extreme 17.44
25.20
3 years
14.60
Extreme 14.6
28.45
5 years
14.60
Extreme 14.6
30.45
10 years
14.60
Extreme 14.6
45.65
More quotes

Managers and Directors - Sinopharm Group Co. Ltd.

Managers TitleAgeSince
Yong Liu PSD
 President 55 09-01-08
Shuang Jun Xu PRN
 Corporate Officer/Principal 55 11-02-28
Zhong Xi Cai PRN
 Corporate Officer/Principal 59 10-04-30
Members of the board TitleAgeSince
Tak Lung Wu BRD
 Director/Board Member 58 20-09-17
Qi Yu Chen BRD
 Director/Board Member 52 10-04-30
Xiao Hui Guan BRD
 Director/Board Member 53 19-01-10
More insiders

ETFs positioned on Sinopharm Group Co. Ltd.

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
2.58% 4 M€ -27.92%
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD ETF KraneShares MSCI All China Health Care Index UCITS ETF - USD
1.36% 1 M€ -23.91% -
KRANESHARES MSCI CHINA ESG LEADERS ETF - USD ETF KraneShares MSCI China ESG Leaders ETF - USD
0.48% 4 M€ -11.56%
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
0.47% 2 M€ -14.14%
More ETFs positioned on Sinopharm Group Co. Ltd.

Quotes

Date Price Change Volume
24-07-02 20.9 +0.48% 503 693
24-07-02 20.8 +0.24% 4,057,738
24-06-28 20.75 +0.97% 5,571,163
24-06-27 20.55 -1.67% 4,016,280
24-06-26 20.9 -2.34% 5,890,324

Delayed Quote Hong Kong S.E., July 02, 2024 at 04:08 am EDT

More quotes

Company Profile

Sinopharm Group Co. Ltd. specialises in the distribution of pharmaceutical products and medical devices to hospitals, clinics, pharmacies and third-party distributors. The group also operates pharmacy chains. Net sales break down by activity as follows: - distribution of pharmaceutical products (71%) ; - distribution of medical devices (21.7%); - operation of directly-owned and franchised pharmacy chains (5.9%); - other (1.4%).
Sector
Pharmaceuticals
Calendar
2024-08-25 - Q2 2024 Earnings Release (Projected)
Related indices
HONG KONG HANG SENG
More about the company

Income Statement Evolution

More financial data

Ratings for Sinopharm Group Co. Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
19.36 CNY
Average target price
24.61 CNY
Spread / Average Target
+27.14%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+1.71% 8.29B
MCKESSON CORPORATION Stock McKesson Corporation
+26.32% 76.05B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-4.23% 23.81B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+15.24% 8.8B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-33.21% 6.77B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+19.66% 5.36B
GALENICA AG Stock Galenica AG
+0.89% 4.06B
EBOS GROUP LIMITED Stock EBOS Group Limited
-8.73% 3.77B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
-9.28% 3.39B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+8.56% 3.28B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 1099 Stock